H1N1 vaccine, SARS virus vaccine, H5N1 vaccine, Enterovirus Type 71 Vaccine, Combined Hepatitis A and Hepatitis B Vaccine

Sinovac H1N1 Influenza A Vaccine

H1N1 Influenza A Vaccine(First pandemic influenza A (H1N1) vaccine approved globally)

Sinovac Hepatitis A Vaccine (Human Diploid Cell), Inactivated

Hepatitis A Vaccine (Human Diploid Cell), Inactivated(A WHO Prequalified Inactivated Hepatitis A Vaccine)

Sinovac Pandemic Influenza Vaccine (inactivated, adjuvanted)

Pandemic Influenza Vaccine (inactivated, adjuvanted)

Sinovac was established in 1993, we engaged in the initial R&D activities that lead to the successful development of the Company’s hepatitis A vaccine in 1999. This is the first inactivated hepatitis A vaccine developed by Chinese scientists.

Over the past two decades, we have developed and commercialized six human-used vaccines and one animal vaccine, and advanced its R&D pipeline. We have developed the world's first inactivated SARS virus vaccine (completed phase I clinical), China's first pandemic influenza (H5N1) vaccine and the world's first influenza A (H1N1) vaccine.

Our 23-valent pneumococcal polysaccharide vaccine, Sabine strain-inactivated polio vaccine (sIPV) and tetravalent influenza virus split vaccine have started production. And the new coronavirus vaccine(COVID-19 vaccine), pneumococcal conjugate vaccine and multiple joint vaccine projects are in clinical or preclinical research.

Moreover, we expanded our fully integrated platform with state-of-the-art research facilities, GMP certified manufacturing facilities, and a sales team with reach across China. We are currently developing a novel vaccine against enterovirus 71, causing the severe hand, foot and mouth disease (HFMD) among the children.